National Cancer Institute CRO Aviano

National Cancer Institute CRO Aviano

Research Institute

Italy | BASIC

About National Cancer Institute CRO Aviano

0 followers

National Cancer Institute CRO-Aviano is an Italian public institute funded in 1984 and is committed to pursue excellence in all aspects of clinical oncology and management of health services. CRO is also an excellence in translational and clinical research activity. Our structure performs an average of 378740 patient exams/year, 8295 pts admitted/year (50% are extra-regional) for medium-long term stays and day hospital treatment. Scientific production sets above of 230 scientific papers in journals with Impact Factor (IF), ranking in the set of the 10% most cited papers in their respective scientific field, having a total IF>1000. Clinical trials average 60 per year.
Research areas
Biological SciencesGenome ResearchCellular and Molecular Biology MarketMedical Health relatedDiagnostic and 4 more
Organization Website
Organization Type
Research Institute
Founded
Headquarters

Publications (6)

Fluidic device that allows high sample volume injection in HPLC systems and provides an automated purification step, reducing sensitivity problems and facilitating the analysis of extracted compounds from complex matrix.[…]

Novel tool for the evaluation of cognitive impairment that interfere with optimum quality of life: 18 items questionnaire with score correlated to clinical outcome and indications.[…]

The effectiveness of many anticancer drugs varies greatly from patient to patient and personalized dosages are required to avoid adverse side effects. The invention provides for the first time an electrochemical method to measure the concentration of the drug Irinotecan in patient's plasma and then […]

The effectiveness of many anticancer drugs varies greatly from patient to patient, with risks of incorrect dosages and adverse side effects. The invention provides for the first time an electrochemical method to measure the concentration of the drug Imatinib in patient's plasma and then to establish[…]

The research group led by Dr Roberta Maestro demonstrated that the overexpression of the protein Twist, detectable in a large fraction of sarcomas but also in a fraction of carcinomas, facilitates the MDM2-mediated degradation of p53 by making p53 more susceptible to MDM2 attack. The p53:MDM2 in[…]

Predictive Kit to identify patients non responding to platinum therapy. 10 gene signature as a predictive biomarker for platinum treatment against different cancer types. The invention consists in quantifying the expression of 10 genes from tumor cells to detect patients eligible for platinum treat[…]

Start collaborating Now!

We are currently seeking best-in-class collaboration partners for the postings listed below. You can respond to current opportunities by browsing the listed entries. We do want to invite you to cooperate with us so please contact us through the available template and we will get in contact with you. Please provide as much detailed information as possible in order to facilitate the engagement process.

Contact Person

LUCIA CORAL

LUCIA CORAL

Knowledge Tranfer Manager at National Cancer Institute CRO Aviano

View Profile

Share this site

FacebookGoogleLinkedInTwitter